(CGEM) Cullinan Oncology - Overview

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US2300311063

Stock: Cancer Drugs, Autoimmune Drugs

Total Rating 37
Risk 65
Buy Signal -1.17
Biotechnology +6.7
Biotechnology +6.7
Market Cap: 795m
Avg Trading Vol: 11.9M USD
ATR: 7.20%
Peers RS (IBD): 78.8
Risk 5d forecast
Volatility 64.9%
Relative Tail Risk -10.5%
Reward TTM
Sharpe Ratio 0.80
Alpha 36.77
Character TTM
Beta 0.532
Beta Downside 1.831
Drawdowns 3y
Max DD 80.41%
CAGR/Max DD 0.08

EPS (Earnings per Share)

EPS (Earnings per Share) of CGEM over the last years for every Quarter: "2021-03": -0.0017, "2021-06": -0.36, "2021-09": -0.4, "2021-12": -0.74, "2022-03": -0.27, "2022-06": 3.77, "2022-09": -0.54, "2022-12": -0.59, "2023-03": -1.42, "2023-06": -0.82, "2023-09": -0.91, "2023-12": -0.54, "2024-03": -0.86, "2024-06": -0.75, "2024-09": -0.69, "2024-12": -0.73, "2025-03": -0.74, "2025-06": -1.19, "2025-09": -0.77, "2025-12": -0.77,
EPS CAGR: -13.04%
EPS Trend: -44.2%
Last SUE: 0.45
Qual. Beats: 0

Revenue

Revenue of CGEM over the last years for every Quarter: 2021-03: 18.943, 2021-06: 0, 2021-09: 0, 2021-12: -37.848114, 2022-03: 0, 2022-06: 0, 2022-09: 0, 2022-12: 0, 2023-03: 0, 2023-06: 0, 2023-09: 0, 2023-12: 0, 2024-03: 0, 2024-06: 0, 2024-09: 0, 2024-12: 0, 2025-03: 0, 2025-06: 0, 2025-09: 0, 2025-12: 0,
Rev. CAGR: 0.00%
Last SUE: -4.00
Qual. Beats: 0

Risks

Technicals: choppy

Description: CGEM Cullinan Oncology March 05, 2026

Cullinan Therapeutics, Inc. (CGEM) is a clinical-stage biopharmaceutical company based in the United States. It focuses on developing treatments for autoimmune diseases and various cancers.

The companys pipeline includes several drug candidates. Zipalertinib, a small molecule, is in Phase 3 trials for non-small cell lung cancer. Other candidates, such as CLN-978 (for lupus and rheumatoid arthritis), CLN-619 (for solid tumors and multiple myeloma), CLN-049 (for acute myeloid leukemia), and CLN-617 (for solid tumors), are in earlier clinical trial phases. The biotechnology sector is characterized by lengthy and expensive drug development processes, with many candidates failing before reaching market.

Cullinan Therapeutics also engages in collaborations, including an agreement with Adimab, LLC for antibody discovery and optimization, and a co-development agreement with Taiho Pharmaceutical Co., Ltd for zipalertinib. The company changed its name from Cullinan Oncology, Inc. in April 2024. Biopharmaceutical companies often rely on strategic partnerships to share development costs and expertise.

To gain further insights into CGEMs financial health and market position, consider exploring its detailed analytics on ValueRay.

Headlines to watch out for

  • Zipalertinib Phase 3 trial results significantly impact stock value
  • Clinical trial success for autoimmune therapies drives growth
  • Regulatory approval timelines for new drugs create volatility
  • Collaboration agreements provide crucial funding and development support
  • Early-stage pipeline progress influences long-term investor confidence

Piotroski VR‑10 (Strict, 0-10) 0.0

Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM)
FCF/TA: -0.39 > 0.02 and ΔFCF/TA -15.84 > 1.0
NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev)
CFO/TA -0.39 > 3% & CFO -175.8m > Net Income -219.9m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 10.25 > 1.5 & < 3
Outstanding Shares: last quarter (59.2m) vs 12m ago 1.06% < -2%
Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin)
Asset Turnover: 0.0% > 50% (prev 0.0%; Δ 0.0% > 0%)
Interest Coverage Ratio: -11.10 > 6 (EBITDA TTM -241.6m / Interest Expense TTM -21.8m)

Altman Z'' -15.00

A: 0.78 (Total Current Assets 386.8m - Total Current Liabilities 37.7m) / Total Assets 448.4m
B: -1.31 (Retained Earnings -588.1m / Total Assets 448.4m)
C: -0.45 (EBIT TTM -241.6m / Avg Total Assets 535.1m)
D: -14.81 (Book Value of Equity -587.1m / Total Liabilities 39.6m)
Altman-Z'' Score: -17.75 = D

Beneish M

DSRI: none (Receivables none/3.00m, Revenue 0.0/0.0)
GMI: 1.00 (fallback, negative margins)
AQI: 0.40 (AQ_t 0.13 / AQ_t-1 0.33)
SGI: none (Revenue 0.0 / 0.0)
TATA: -0.10 (NI -219.9m - CFO -175.8m) / TA 448.4m)
Beneish M-Score: cannot calculate (missing components)

What is the price of CGEM shares?

As of March 23, 2026, the stock is trading at USD 12.74 with a total of 1,713,186 shares traded.
Over the past week, the price has changed by -9.19%, over one month by -8.93%, over three months by +23.21% and over the past year by +49.18%.

Is CGEM a buy, sell or hold?

Cullinan Oncology has received a consensus analysts rating of 4.89. Therefore, it is recommended to buy CGEM.
  • StrongBuy: 8
  • Buy: 1
  • Hold: 0
  • Sell: 0
  • StrongSell: 0

What are the forecasts/targets for the CGEM price?

Issuer Target Up/Down from current
Wallstreet Target Price 31.4 146.1%
Analysts Target Price 31.4 146.1%

CGEM Fundamental Data Overview March 20, 2026

P/E Forward = 6.3012
P/S = 26.8794
P/B = 1.9473
Revenue TTM = 0.0 USD
EBIT TTM = -241.6m USD
EBITDA TTM = -241.6m USD
Long Term Debt = 2.68m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 780k USD (from shortTermDebt, last quarter)
Debt = 2.68m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -85.6m USD (from netDebt column, last quarter)
Enterprise Value = 419.5m USD (794.7m + Debt 2.68m - CCE 377.9m)
Interest Coverage Ratio = -11.10 (Ebit TTM -241.6m / Interest Expense TTM -21.8m)
EV/FCF = -2.39x (Enterprise Value 419.5m / FCF TTM -175.8m)
FCF Yield = -41.91% (FCF TTM -175.8m / Enterprise Value 419.5m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 232k) / Revenue TTM)
Tobins Q-Ratio = 0.94 (Enterprise Value 419.5m / Total Assets 448.4m)
Interest Expense / Debt = 172.0% (Interest Expense 4.62m / Debt 2.68m)
Taxrate = 21.0% (US default 21%)
NOPAT = -190.9m (EBIT -241.6m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 10.25 (Total Current Assets 386.8m / Total Current Liabilities 37.7m)
Debt / Equity = 0.01 (Debt 2.68m / totalStockholderEquity, last quarter 408.7m)
Debt / EBITDA = 0.35 (negative EBITDA) (Net Debt -85.6m / EBITDA -241.6m)
Debt / FCF = 0.49 (negative FCF - burning cash) (Net Debt -85.6m / FCF TTM -175.8m)
Total Stockholder Equity = 476.0m (last 4 quarters mean from totalStockholderEquity)
RoA = -41.09% (Net Income -219.9m / Total Assets 448.4m)
RoE = -46.19% (Net Income TTM -219.9m / Total Stockholder Equity 476.0m)
RoCE = -50.48% (EBIT -241.6m / Capital Employed (Equity 476.0m + L.T.Debt 2.68m))
RoIC = -40.10% (negative operating profit) (NOPAT -190.9m / Invested Capital 476.0m)
WACC = 7.82% (E(794.7m)/V(797.4m) * Re(7.85%) + (debt cost/tax rate unavailable))
Discount Rate = 7.85% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.92%
Shares Correlation 3-Years: 100.0 | Cagr: 17.62%
[DCF] Fair Price = unknown (Cash Flow -175.8m)
EPS Correlation: -44.16 | EPS CAGR: -13.04% | SUE: 0.45 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: 0.0% | SUE: -4.0 | # QB: 0
EPS next Quarter (2026-06-30): EPS=-0.88 | Chg7d=+0.105 | Chg30d=+0.077 | Revisions Net=+3 | Analysts=7
EPS current Year (2026-12-31): EPS=-3.10 | Chg7d=+0.196 | Chg30d=+0.303 | Revisions Net=+2 | Growth EPS=+7.8% | Growth Revenue=+0.0%
EPS next Year (2027-12-31): EPS=-2.92 | Chg7d=+0.067 | Chg30d=-0.224 | Revisions Net=+2 | Growth EPS=+5.6% | Growth Revenue=+98.8%
[Analyst] Revisions Ratio: +1.00 (3 Up / 0 Down within 30d for Next Quarter)

Additional Sources for CGEM Stock

Fund Manager Positions: Dataroma | Stockcircle